Here we report the use of C5-propynyl-dU,dC-phosphorothioate antisense oligonucleotides to inhibit IGF-I receptor expression in keratinocytes. We identified several inhibitory antisense ...

The discovery could pave the way for a groundbreaking RNA-based multi-cancer treatment. Alternative RNA splicing functions ...

By using antisense oligonucleotides (ASOs) to restore poison exon activity, the team effectively reactivated this kill switch, offering a potential new precision therapy for aggressive ...

Antisense oligonucleotide (ASO) technology has accelerated drug discovery in the last few decades with several ASO-based drugs currently approved by FDA and many more being investigated in clinical ...

The upcoming Therapeutic Oligonucleotides 2025 conference, hosted by ELRIG, will take place at AstraZeneca’s R&D site in ...

Therapeutic oligonucleotides act on different stages of pathological gene expression. Standard schematic of oligonucleotide activities in pathogenesis disease progression. Decoys bind to transcription ...

ELRIG, a not-for-profit, volunteer-led organization for the drug discovery community, today announced the keynote speakers for Therapeutic Oligonucleotides 2025 taking place at the AstraZeneca R&D ...

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable ...